A poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy for the patients with BRCA mutation (germline and or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies.
Trade name Rubraca.
Recommended dose 600 mg orally twice daily.
Phase II trial reveald an objective response rate of 80% in patients with BRCA mutation.
The drug is continued until disease progression or unacceptable toxicity.
Indicated for BRCA mutation associated advanced ovarian cancer or have been treated with two prior chemotherapy agents
The glands that secrete hormones comprise the endocrine system.
Most common adverse reactions are nausea, fatigue, vomiting, anemia, abdominal pain, dysguesia, constipation, impaired appetite, diarrhea, thrombocytopenia, and dyspnea.
Most common laboratory abnormalities include increased creatinine, increased ALT and AST, decrease in hemoglobin, decreased lymphocytes, increasing cholesterol, decrease in platelets, and a decrease in absolute neutrophil count.
In a clinical trial the response rate was 54%, 9% complete response 45% partial response, and a median duration of response of 9.2 months.
In phase III ARIEL trial for patients with BRCA mutations, there was a 77% reduction in the risk of death vs. placebo, and a median PFS of 16.6 months compared to 5.4 months with placebo.
May be efficacious in BRCA mutation in pancreatic cancers.
The duration of progressive free survival is significantly longer with Rucaparib than with control medication among patients who have metastatic, castrate resistant prostate cancer with a BRCA alteration.